Form 4: Aldeyra Therapeutics Director Acquires Stock Options

Aldeyra Therapeutics Director Gary M. Phillips acquired stock options for 70,000 shares of common stock.

Summary

• Gary M. Phillips, a Director at Aldeyra Therapeutics, Inc., acquired stock options on June 9, 2026.
• The options grant the right to purchase common stock at an exercise price of $1.72 per share.
• Phillips acquired options for 70,000 shares, with vesting contingent on continuous service.
• Additional options were acquired for 6,636 shares related to service on the Compensation Committee and 4,977 shares for service on the Audit Committee.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard stock option grant to a director, indicating continued engagement and potential future upside if the stock performs well.

Positives

• Director Gary M. Phillips has acquired a significant number of stock options, indicating confidence in the company's future.
• The acquisition of options for 70,000 shares, plus additional options tied to committee service, suggests a commitment to the company's governance and performance.

Risks

• Vesting of the acquired stock options is contingent upon the Reporting Person providing continuous service to the Issuer through the applicable vesting dates.
• The exercise price of $1.72 per share means the options will only be profitable if the stock price rises above this level.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the value of these options is directly tied to an increase in share price.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as an incentive to align management's interests with those of shareholders and to retain key talent.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be seen as a positive signal of confidence in the company's future performance, potentially aligning director incentives with shareholder value.
• Employees: While not directly impacting all employees, such grants can contribute to a culture of shared success if the company's stock price increases.

Next Steps

• Reporting Person must provide continuous service to the Issuer through the applicable vesting dates for options to become exercisable.
• The options are exercisable until their expiration date of June 8, 2036.

Key Dates

Keywords

Aldeyra Therapeutics, ALDX, Form 4, Stock Options, Director, Beneficial Ownership, Securities, SEC Filing